Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Baf01396595afec33d8b7599134b3a6ed> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Baf01396595afec33d8b7599134b3a6ed NCIT_P378 "NCI" @default.
- Baf01396595afec33d8b7599134b3a6ed type Axiom @default.
- Baf01396595afec33d8b7599134b3a6ed annotatedProperty IAO_0000115 @default.
- Baf01396595afec33d8b7599134b3a6ed annotatedSource NCIT_C184308 @default.
- Baf01396595afec33d8b7599134b3a6ed annotatedTarget "A radiopharmaceutical agent comprised of a pegylated cyclic arginine-glycine-aspartic acid (RGD) dimer (PRGD2) labeled with lutetium Lu 177, with potential antineoplastic activity against alphaVbeta3 integrin-expressing tumor cells. Upon administration of lutetium Lu 177 AB-3PRGD2, the RGD moiety binds to alphaVbeta3 integrin on alphaVbeta3 integrin-expressing tumor cells. The tumor cells can be eradicated upon direct cytotoxicity through beta radiation. AlphaVbeta3 integrin, a member of the integrin receptor family, is overexpressed on certain tumor cells and tumor endothelial cells while minimally or not expressed on healthy, normal cells; this receptor plays a key role in angiogenesis, tumor proliferation and survival." @default.